Levitra 20 mg

Clinical Monograph: Levitra 20 mg (Vardenafil Hydrochloride)

1. Classification and Chemical Overview

Vardenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor belonging to the imidazotriazinone chemical class. Chemically designated as 3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4triazin-2-yl)-4-ethoxyphenylsulfonyl]-4-methylpiperazine monohydrochloride. Under the Anatomical Therapeutic Chemical (ATC) system, vardenafil is indexed under G04BE09.

• Product Context: Levitra is a well-known brand-name formulation originally developed by Bayer. The 20 mg strength represents the maximum recommended single unit dose of vardenafil, prescribed when lower strengths (such as 5 mg or 10 mg) yield insufficient clinical efficacy while maintaining acceptable tolerability.

• Controlled Status: Regulated as a Prescription Only Medicine (POM). It is not classified as a controlled substance, as it lacks reinforcing central nervous system properties, dependence liability, or abuse potential.

2. Mechanism of Action and Pharmacodynamics

Vardenafil facilitates erectile function by enhancing the physiological nitric oxide signaling cascade during sexual stimulation:

• Nitric Oxide / cGMP Pathway: Sexual stimulation triggers the local release of nitric oxide (NO) in the corpus cavernosum. Nitric oxide activates guanylyl cyclase, increasing intracellular levels of cyclic guanosine monophosphate (cGMP), which relaxes smooth muscle and allows blood inflow to produce an erection.

• PDE5 Inhibition: Vardenafil competitively inhibits phosphodiesterase type 5 (PDE5), the enzyme responsible for degrading cGMP in the corpus cavernosum.

• Potentiated Response: By preventing cGMP breakdown, vardenafil preserves elevated cGMP concentrations, amplifying smooth muscle relaxation and rigidity during sexual arousal. It has no direct erectogenic effect in the absence of sexual stimulation.

3. Approved Clinical Indications and Dosing Scope

Licensing for Levitra 20 mg includes:

• Erectile Dysfunction (ED): Treatment of erectile dysfunction, defined as the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.

Dosing & Administration Regimen:

• On-Demand Dosing: Typically administered orally approximately 25 to 60 minutes prior to anticipated sexual activity. Sexual stimulation is required for the drug to be effective.

• Frequency Restrictions: Do not exceed one dose per 24-hour period.

• Strength Scope & Titration: Therapy is generally initiated at 10 mg. The 20 mg strength is reserved for patients requiring maximum clinical potency who have demonstrated good tolerability to lower doses.

• Special Populations: Reduced starting doses (e.g., 5 mg) are recommended for elderly patients (aged 65 and older), those with mild-to-moderate hepatic impairment, or individuals taking concurrent moderate CYP3A4 inhibitors.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Rapidly absorbed following oral administration, with peak plasma concentrations (Cmax​) achieved within 30 to 120 minutes (median 60 minutes). High-fat meals can reduce absorption rate and lower Cmax​.

• Distribution: Distributes extensively into body tissues, with high plasma protein binding (~94%). Protein binding is independent of total drug concentrations.

• Biotransformation: Extensively metabolized primarily in the liver via hepatic Cytochrome P450 enzymes (CYP3A4, with minor contributions from CYP3A5 and CYP2C9 isoforms) into active and inactive metabolites (such as desethylvardenafil).

• Elimination: Excreted predominantly as metabolites via the feces (~91% to 95%) and to a lesser extent in the urine (~2% to 6%). The terminal elimination half-life averages 4 to 5 hours.

5. Physiological Effects and Adverse Event Spectrum

Vardenafil induces systemic vasodilation, smooth muscle relaxation, and mild autonomic modulation.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Headache, flushing.

• Common ($\ge 1/100$ to $<1/10$): Dizziness, dyspepsia, nasal congestion, nausea, rhinitis.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Visual disturbances (including color tint vision, blurred vision, chromatopsia), somnolence, dyspnea, hypotension, orthostatic hypotension, hypertension, palpitations, tachycardia, muscle spasm, rash, gastrointestinal reflux.

• Rare / Severe (<1/1,000): Sudden vision loss (non-arteritic anterior ischemic optic neuropathy – NAION), sudden hearing loss or deafness, severe cardiovascular events (myocardial infarction, unstable angina, ventricular arrhythmias), priapism (prolonged, painful erections exceeding 4 hours), and severe hypersensitivity reactions (including angioedema).

6. Contraindications, Drug Interactions, and Clinical Precautions

Controindicazioni

• Known hypersensitivity to vardenafil or formulation excipients.

• Concomitant Nitrates or Nitric Oxide Donors: Absolute contraindication. Co-administration with organic nitrates (e.g., nitroglycerin, isosorbide dinitrate, amyl nitrite “poppers”) can trigger profound, life-threatening systemic hypotension.

• Concomitant Guanylate Cyclase Stimulators: Co-administration with riociguat is strictly contraindicated due to synergistic hypotensive effects.

• Potent CYP3A4 Inhibitors: Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, indinavir) is contraindicated.

• Severe Cardiovascular Disease: Patients with unstable angina, severe heart failure, recent myocardial infarction or stroke within the last 6 months, or life-threatening arrhythmias.

• Severe hepatic or end-stage renal impairment requiring dialysis.

Key Drug Interactions

• Alpha-Blockers (e.g., Tamsulosin, Doxazosin): Co-administration can provoke symptomatic postural hypotension and dizziness; patients must be stabilized on alpha-blocker therapy before initiating low-dose vardenafil.

• Potent CYP3A4 Inhibitors: Significantly increase vardenafil plasma exposure and toxicity risks.

• Antiarrhythmic Agents (Class IA or III): Vardenafil can cause mild, transient QT interval prolongation; caution is advised when co-administered with drugs known to prolong the QT interval (e.g., amiodarone, sotalol, quinidine).

Clinical Precautions and Monitoring

• Cardiovascular Status Evaluation: Because sexual activity carries an inherent cardiac risk, evaluate the patient’s cardiovascular status prior to initiating treatment for erectile dysfunction.

• Priapism Warning: Instruct patients to seek immediate medical attention if an erection persists continuously for 4 hours or more, as prolonged corporal ischemia can result in permanent erectile tissue damage.